Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies : Episode 3
Opinion
Video
Dynamics of ESR1 Alterations and Serial Liquid Biopsies
In their discussion, medical experts in the field of breast cancer explore the role of liquid biopsies and compare the significance of ESR1 mutations to other biomarkers, such as PIK3CA, in terms of their driver versus passenger status in the context of HR+/HER2- breast cancer.
EP: 1.Prevalence and Testing Strategies for ESR1
EP: 2.Evolution of Testing Strategies for ESR1
Now Viewing
EP: 3.Dynamics of ESR1 Alterations and Serial Liquid Biopsies
EP: 4.Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
EP: 5.EMERALD Study Design and Results for Elacestrant
EP: 6.Evolving Best Practices for ESR1 Testing
EP: 7.Case Presentation 2: Co-mutations in ESR1 and PIK3CA
EP: 8.PIK3CA Mutations and Delivering PI3K Inhibitors
EP: 9.PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors
EP: 10.Combinations and Treatment Sequence Strategies in Breast Cancer
EP: 11.Future Directions and Unmet Needs in HR+ Breast Cancer
EP: 12.Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer
- Can you explain the functional consequences of different ESR1 mutations on estrogen receptor signaling and endocrine resistance?
- How does it change the way you test? Liquid v solid tissue
- How and when are you testing?
- How do ESR1 mutations compare to other biomarkers like PIK3CA in terms of their driver vs passenger status in HR+/HER2- breast cancer?
- How does it change the way you test? Liquid v solid tissue
Related Videos
Related Content
